Tarmat is an infrastructure construction company that specializes in building and resurfacing airport runways, taxi tracks, and highways for government agencies and private airport operators.
The company operates in a highly competitive, tender-based industry where contracts are awarded to the lowest bidder. While specialized airport work requires technical certification, the company's extremely low average ROCE of 2.2% and negative net margins indicate a total lack of pricing power or cost advantage.
Management has struggled to generate positive returns on capital, with historical ROE and net margins averaging below zero. Recent capital activity involves issuing warrants and preferential shares to fund operations rather than returning value to shareholders through dividends.
The company's demise was driven by the crystallization of its opaque joint venture risks and chronic liquidity mismanagement. The auditor's inability to value the Backbone-Tarmat-Al Fara'a JV eventually led to a massive write-down, while the persistent failure to remit statutory dues signaled a terminal cash crunch. As receivables aged and remained uncollected, the company was forced into dilutive equity raises just to sustain operations, ultimately eroding book value and leaving shareholders with a shell of a business that could no longer compete for high-stakes airport tenders.
RichFakir rates Tarmat Ltd's business quality as poor — 17/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Tarmat Ltd is trading about 34% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Tarmat Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Tarmat Ltd's fair value is about ₹41 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →